UC Davis Alzheimer's Disease Research Center

加州大学戴维斯分校阿尔茨海默病研究中心

• 批准号: 10461120
• 负责人: Charles DeCarli
• 金额: $ 317.86万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10461120
• 关键词: Address; Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease risk; Area; Autopsy; Awareness; Biological Markers; Blood; Caregiver research; Caring; Characteristics; Clinical; Cognition; Cognitive; Communities; Data; Database Management Systems; Databases; Dementia; Development; Diagnosis; Disease; Early Diagnosis; Educational Status; Elderly; Environment; Fostering; Funding; Future; Goals; Health Professional; Healthcare; Heterogeneity; Image; Impaired cognition; Individual; International; Intervention; Investigation; Lead; Measures; Mentors; Methods; Mission; Outcome; Participant; Pathologic; Pathology; Persons; Phenotype; Population; Population Heterogeneity; Prevention; Prevention strategy; Research; Research Activity; Research Design; Research Infrastructure; Research Methodology; Research Personnel; Research Support; Resources; Risk; Risk Factors; Risk Reduction; Scanning; Science; Secure; Services; Technology; Training and Education; Translational Research; Vascular Diseases; Vision; aging brain; brain health; career; caregiving; cohort; collaborative environment; dementia risk; design; disparity reduction; education research; effective therapy; epidemiology study; ethnic minority; high risk; imaging biomarker; improved; innovation; insight; interdisciplinary collaboration; interest; neuropathology; next generation; novel; prevent; racial and ethnic; racial minority population; recruit; stem; therapy development; tool; training opportunity

PROJECT SUMMARY/ABSTRACT - Overall The mission of the UC Davis Alzheimer’s Disease Research Center (UCD ADRC) is to promote a highly innovative and enriched research environment focused on understanding the heterogeneity of brain aging among diverse populations that will ultimately lead to effective therapies to prevent or mitigate dementia. This approach stems from the premise that emphasizing diversity enhances discovery and contributes to translational science as well as reducing disparities in brain health and care. To accomplish this mission, the UCD ADRC has developed innovative methods and a unique study design to recruit and retain a highly demographically diverse clinical and autopsy cohort. All UCD ADRC participants are longitudinally followed and deeply phenotyped with extensive clinical, blood and imaging biomarker measures as well as developing state-of-the-art quantitative neuropathology. The UCD ADRC succeeds at these efforts through a robust research infrastructure, state-of-the-art database management and a highly collaborative environment consisting of seven well integrated resource cores and one research education component (REC) designed to facilitate new research efforts and interventions, dissemination of research findings, education and training as well as encouraging researcher development. Our approach addresses several milestones set by the National Alzheimer’s Project Act to effectively treat Alzheimer’s disease and associated disorders (ADRD) by 2025. These include, but are not limited to: 1) M1.L., evaluating disparities among ethnic and racial minority populations that are at higher risk for AD to mitigate risk and improve cognitive outcomes, 2) M2.H., fully characterizing mixed pathologies and identifying unique risk factors,3) M5-7., accelerating the development of treatments that would prevent, halt, or reverse the course of Alzheimer’s disease (AD), 4) M9., improving early diagnosis through discovery of novel imaging and blood biomarkers, 5) M8., developing novel dementia prevention strategies, and 6) M13.E.,supporting caregiving through funded caregiver research. The UCD ADRC also directly supports multiple epidemiological studies of diverse communities through use of research methods and personnel to gain further insights into dementia risk reduction, early diagnosis, and the impact of various neuropathologies on aging and dementia. Our efforts reflect the evolving needs of an increasingly older and more diverse US population, which is expected to rise to nearly 14 million by midcentury. Moreover, while AD continues to be the major pathological cause of dementia, more recent studies—including one from the UCD ADRC—find that dementia pathology is multifactorial and highly heterogeneous, due in part to the co-occurrence of AD and vascular disease, which varies by ethnoracial characteristics, is emphasized as part of dementia prediction and which can be modified by treatment even in later life. The UCD ADRC is uniquely qualified to support this research focus with a considerable impact on future ADRD diagnosis and treatment.

项目概要/摘要 - 总体 加州大学戴维斯分校阿尔茨海默病研究中心 (UCD ADRC) 的使命是促进高度 创新且丰富的研究环境，专注于了解大脑衰老的异质性 在不同人群中进行研究，最终将带来预防或减轻痴呆症的有效疗法。 这种方法源于这样一个前提：强调多样性可以增强发现并有助于 转化科学以及减少大脑健康和护理方面的差异。为了实现这一点 使命，UCD ADRC 开发了创新方法和独特的研究设计来招募和保留 人口统计学高度多样化的临床和尸检队列。所有 UCD ADRC 参与者都是纵向的 通过广泛的临床、血液和成像生物标志物测量以及 发展最先进的定量神经病理学。 UCD ADRC 通过以下措施取得了这些努力的成功： 强大的研究基础设施、最先进的数据库管理和高度协作的环境 由七个整合良好的资源核心和一个研究教育组件（REC）组成，旨在 促进新的研究工作和干预措施、研究成果的传播、教育和培训 以及鼓励研究人员的发展。我们的方法解决了国家设定的几个里程碑 阿尔茨海默病项目法案旨在到 2025 年有效治疗阿尔茨海默病及相关疾病 (ADRD)。 这些包括但不限于：1) M1.L.，评估少数族裔和种族之间的差异 AD 风险较高的人群可以降低风险并改善认知结果，2) M2.H.，完全 表征混合病理并确定独特的风险因素，3) M5-7.，加速发展 预防、停止或逆转阿尔茨海默病 (AD) 病程的治疗方法，4) M9.，早期改善 通过发现新的成像和血液生物标志物进行诊断，5) M8.，发展出新的痴呆症 预防策略，以及 6) M13.E.，通过资助护理人员研究来支持护理。都柏林大学 ADRC 还通过研究直接支持不同社区的多项流行病学研究 方法和人员，以进一步了解痴呆症风险降低、早期诊断以及痴呆症的影响 有关衰老和痴呆的各种神经病理学。 我们的努力反映了日益老龄化和更加多样化的美国人口不断变化的需求， 预计到本世纪中叶将增加到近 1400 万。此外，虽然 AD 仍然是主要的病理 痴呆症的病因，最近的研究（包括来自 UCD ADRC 的一项研究）发现，痴呆症的病理学是 多因素和高度异质性，部分原因是 AD 和血管疾病同时发生， 因民族特征而异，作为痴呆症预测的一部分被强调，并且可以修改 即使在晚年也能通过治疗。 UCD ADRC 具有独特的资格来支持这一研究重点 对未来ADRD的诊断和治疗产生重大影响。